Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,417 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active capsule Clear all
Completed Phase 3 Interventional Results available

Treatment of Chlamydia Infection Comparing WC2031 Tablets With Vibramycin

NCT01113931
View directory record Official record
Conditions
Urogential Chlamydia Trachomatis Infection
Interventions
Doxycyline Hyclate tablet, Vibramycin (doxycyline hyclate) capsule
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
19 Years to 45 Years
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
43
States / cities
Birmingham, Alabama • Foley, Alabama • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2012 · Synced Oct 29, 2026, 2:33 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

NCT06087653
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Lenalidomide 25 MG Oral Capsule
Drug
Lead sponsor
Starton Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Wilson, North Carolina • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 29, 2026, 2:33 AM EDT
Completed Not applicable Interventional

A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss

NCT04450602
View directory record Official record
Conditions
Androgenetic Alopecia, Androgenic Alopecia, Telogen Effluvium, Thinning Hair, Hair Loss/Baldness, Hair Thinning
Interventions
ALRV5XR, ALRV5XR Shampoo, ALRV5XR Conditioner, ALRV5XR Hair Follicle Serum (Nutriment), Placebo, Placebo Shampoo, Placebo Conditioner, Placebo Hair Follicle Serum (Nutriment)
Dietary Supplement · Other
Lead sponsor
Arbor Life Labs
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 29, 2026, 2:33 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations

NCT03670953
View directory record Official record
Conditions
Parkinson's Disease (Disorder)
Interventions
IR CD-LD, IPX203 ER CD-LD, Placebo Matching IPX203, Placebo Matching IR CD-LD
Drug · Other
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
40 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
56
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 29, 2026, 2:33 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

NCT04993729
View directory record Official record
Conditions
Acute Mountain Sickness (AMS)
Interventions
T89 capsule, Placebo capsule
Drug
Lead sponsor
Tasly Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
853 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 29, 2026, 2:33 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Shatavari Root Extract for Perimenopausal Symptoms

NCT07441109
View directory record Official record
Conditions
Perimenopause, Women Health
Interventions
Shatavari (Asparagus racemosus) Root Extract, Placebo Capsule
Dietary Supplement · Other
Lead sponsor
SF Research Institute, Inc.
Network
Eligibility
40 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 29, 2026, 2:33 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients

NCT01335464
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
placebo, BIBF 1120
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
24
States / cities
Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Oct 29, 2026, 2:33 AM EDT
Completed Phase 1Phase 2 Interventional

Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection

NCT00911963
View directory record Official record
Conditions
Hepatitis C
Interventions
VCH-222 or matching placebo, peginterferon alfa-2a, ribavirin
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Marietta, Georgia • Detroit, Michigan • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Oct 29, 2026, 2:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Glutathione Supplementation in Older Healthy Adults and Its Effect on the Number of Healthy Days Experienced During Four Months of Supplementation Compared to Placebo

NCT02438956
View directory record Official record
Conditions
Improvement in Immune Cell Function in Elderly Humans
Interventions
Setria glutathione supplement, Crystalline Cellulose
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
50 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Oct 29, 2026, 2:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Probiotic Intake on Intestinal Permeability in Healthy Adults

NCT03611400
View directory record Official record
Conditions
Intestinal Barrier Function
Interventions
Probiotic, Placebo
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 50 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 21, 2019 · Synced Oct 29, 2026, 2:33 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Assessment of DHA On Reducing Early Preterm Birth

NCT02626299
View directory record Official record
Conditions
Preterm Birth
Interventions
Docosahexaenoic acid - 800mg/day, Docosahexaenoic acid - 200mg/day, Placebo
Drug · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
3
States / cities
Kansas City, Kansas • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 29, 2026, 2:33 AM EDT
Completed Phase 3 Interventional Results available

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting

NCT02493777
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200 methylphenidate hydrochloride (MPH) Capsules, Placebo
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Newport Beach, California • Bradenton, Florida • Maitland, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 29, 2026, 2:33 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Development of Agents to Diminish the Risk of Hypoglycemia-induced Brain Injury in Type 1 Diabetes

NCT03356457
View directory record Official record
Conditions
Hyperglycaemia (Diabetic)
Interventions
Dichloroacetate, Placebo oral capsule
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 29, 2026, 2:33 AM EDT
Not yet recruiting Phase 2 Interventional

Ginger's Therapeutic Potential in Asthma

NCT07792395
View directory record Official record
Conditions
Asthma
Interventions
Ginger Extract, Placebo
Drug
Lead sponsor
Emily DiMango, MD
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 29, 2026, 2:33 AM EDT
Completed Phase 2 Interventional

N-Acetylcysteine and Smoking Reduction

NCT00751257
View directory record Official record
Conditions
Nicotine Dependence
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 29, 2026, 2:33 AM EDT
Not yet recruiting Phase 3 Interventional

Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial

NCT07148206
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Dronabinol Capsules, Epidiolex 100 mg/mL Oral Solution, Placebo Dronabinol, Placebo Epidiolex
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 29, 2026, 2:33 AM EDT
Completed Phase 3 Interventional Results available

Randomized, Double-Blind, Single-Dose, Efficacy and Safety Study of Test Acetaminophen Tablet in Postoperative Dental Pain

NCT03224403
View directory record Official record
Conditions
Post-operative Dental Pain
Interventions
Test acetaminophen, Commercial acetaminophen, Commercial ibuprofen, Placebo
Drug
Lead sponsor
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division
Industry
Eligibility
17 Years to 50 Years
Enrollment
664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 15, 2021 · Synced Oct 29, 2026, 2:33 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis

NCT00626275
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ADL5859, Naproxen, Placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
8
States / cities
Trumbull, Connecticut • Daytona Beach, Florida • Wheaton, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Oct 29, 2026, 2:33 AM EDT
Recruiting Phase 2 Interventional

Influence of β-hydroxy β-methyl Butyrate (HMB)Supplementation on Post-operative Muscle Mass and Function in Female Athletes

NCT05869812
View directory record Official record
Conditions
Atrophy
Interventions
CaHMB (Dietary supplement, not Drug), CaLa
Drug · Dietary Supplement
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 29, 2026, 2:33 AM EDT
Completed Phase 2 Interventional

A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects

NCT00367887
View directory record Official record
Conditions
Hepatitis C
Interventions
Peg-Intron, REBETOL, HCV 796
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
34
States / cities
Anaheim, California • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 29, 2026, 2:33 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis

NCT00808132
View directory record Official record
Conditions
Menopause, Osteoporosis
Interventions
bazedoxifene 20 mg/ conjugated estrogens 0.45 mg, bazedoxifene 20 mg/ conjugated estrogens 0.625 mg, bazedoxifene 20 mg, conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 64 Years · Female only
Enrollment
1,886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
143
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 29, 2026, 2:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Oral Adenosine-triphosphate (ATP) on Human Muscle Performance

NCT01141504
View directory record Official record
Conditions
Healthy Subjects
Interventions
PeakATP 250, Placebo, PeakATP 400, PeakATP 400 plus proprietary blend
Dietary Supplement
Lead sponsor
Metabolic Technologies Inc.
Industry
Eligibility
20 Years to 30 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 10, 2012 · Synced Oct 29, 2026, 2:33 AM EDT
Completed Early Phase 1 Interventional Results available

Ginger's Therapeutic Potential in Asthma

NCT03705832
View directory record Official record
Conditions
Asthma
Interventions
Ginger Extract, Placebo
Drug
Lead sponsor
Emily DiMango, MD
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 29, 2026, 2:33 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients

NCT03833206
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
PDC-1421 Capsule
Drug
Lead sponsor
BioLite, Inc.
Industry
Eligibility
21 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 29, 2026, 2:33 AM EDT